Exclusive: In Russia, a black market for HIV drug to try on coronavirus [Reuters (UK)]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Reuters
Exclusive: In Russia, a black market for HIV drug to try on coronavirus - Reuters 6 Min Read MOSCOW (Reuters) - A black market has developed in Russia for an antiviral HIV drug explored as a possible treatment for COVID-19, the respiratory disease caused by the new coronavirus, according to sellers, HIV activists and the head of the drug’s main Russian producer. More than 20 trials around the world are testing Kaletra as a COVID-19 treatment or post-exposure prophylaxis. Russia’s Health Ministry recommended it as a possible treatment for COVID-19 at the end of January after reports from China that it was beneficial, but later added that its efficacy was uncertain. That did not deter speculators who bet that shortages of the drug, also produced as a generic in Russia under the name Kalidavir, might arise as the coronavirus spread. “Three months ago, people were buying Kaletra from us without much enthusiasm for 900 roubles ($12) a box,” one online trader of HIV drugs said. “Now, antici
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- The 3 Most Reliable Dividend Stocks to Buy for Years to Come [Yahoo! Finance]Yahoo! Finance
- Could Buying This Stock Today Pay Off Big Over the Next 5 Years? [Yahoo! Finance]Yahoo! Finance
- AbbVie Call Options Spike 2,599%: Tracking the Big Bet [Yahoo! Finance]Yahoo! Finance
- Emmecell Appoints Ramin Valian as Chief Executive Officer to Advance Magnetic Cell Delivery Platform [Yahoo! Finance]Yahoo! Finance
- AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)PR Newswire
ABBV
Earnings
- 10/31/25 - Beat
ABBV
Sec Filings
- 1/7/26 - Form 8-K
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- ABBV's page on the SEC website